Main Article Content
ozone, autohaemotherapy, soft-tissue infections, wound healing, diabetes mellitus type 2, basic fibroblast growth factor, fibroblast growth factor receptors
Background and aim: We aimed to investigate the effect of OA on the wound healing, serum values of interleukin (IL) - 6, 8, 10, tumor necrosis factor-alpha (TNF-α), basic fibroblast growth factor (bFGF) and local expression of fibroblast growth factor receptors (FGFR) in type 2 diabetics with the acute soft-tissue infections.
Methods: Patients in the first cohort (n-30) received a basic comprehensive treatment (BCT-group), and the second (n=28) also received OA (OA-group). Blood samples for ELISA and tissue specimens for the immunohistochemical examinations were collected at admission (day 0) and at the 9th day of inpatient treatment.
Results: The additional using of OA has accelerated the timing of a single and the complete wound granulation and the timing to marginal epithelization, compared with the results of the standard treatment. The use of OA has significantly reduced the production of IL-8, 10 at 9th day. OA-group patients were characterized by consistently high levels of bFGF production in contrast to the BCT-group, where the decreasing in the serum bFGF level was observed. The maximum number of bFGFR - immunopositive labels was observed in OA-group out to 9th day (319,45 (249,90-348,43) versus baseline 192,65 (171,93-207,72), versus BCT-group 123,30 (105,23- 141,10), p<0,001).
Conclusions: Application of OA in the complex treatment of the acute soft-tissue infections in diabetics makes it possible to achieve the significant reductions in the duration of the wound inflammation and regeneration phases by eliminating of overproduction of IL- 8, 10 and induction of expression of bFGF and its receptors.
2. Suaya JA, Eisenberg DF, Fang C, Miller LG. Skin and soft tissue infections and associated complications among commercially insured patients aged 0–64 years with and without diabetes in the U.S. PLoS One 2013; 8 (4): e60057. doi: 10.1371/journal.pone.0060057.
3. Mustăţea P, Bugă C, Doran H et al. Soft tissue infections in diabetic patients. Chirurgia (Bucur) 2018; 113 (5): 651-67.
4. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007; 23 (1): 3-13.
5. Demidova-Rice TN, Hamblin MR, Herman IM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 1: normal and chronic wounds: biology, causes, and approaches to care. Adv Skin Wound Care 2012; 25 (7): 304–14.
6. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8 (3): 235–53.
7. Freiin von Hövel F; Kefalakes E; Grothe C. What can we learn from FGF-2 isoform specific mouse mutants? Differential insights into FGF-2 physiology in vivo. Int J Mol Sci 2021; 22 (1): 390. doi: 10.3390/ijms22010390.
8. Shi HX, Lin C, Lin BB et al. The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo. PLoS One 2013; 8 (4): e59966. doi: 10.1371/journal.pone.0059966.
9. Komi-Kuramochi A., Kawano M., Oda Y et al. Expression of fibroblast growth factors and their receptors during full-thickness skin wound healing in young and aged mice. J Endocrinol 2005; 186 (2): 273-89.
10. Meyer M, Müller AK, Yang J et al. FGF receptors 1 and 2 are key regulators of keratinocyte migration in vitro and in wounded skin. J Cell Sci 2012; 125 (23): 5690-701.
11. Shah JM, Omar E, Pai DR, Sood S. Cellular events and biomarkers of wound healing. Indian J Plast Surg 2012; 45 (2): 220-8.
12. Marti-Carvajal AJ, Gluud C, Nicola S et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev 2015; 10: CD008548. doi:10.1002/14651858.CD008548.pub2.
13. Fernandez-Montequin JI, Betancourt BY, Leyva-Gonzalez G et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: Treatment up to complete wound closure. Int Wound J 2009; 6 (1): 67–72.
14. Loot MA, Kenter SB, Au FL et al. Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol 2002; 81 (3): 153–60.
15. Cowin AJ, Hatzirodos N, Holding CA. et al. Effect of healing on the expression of transforming growth factor beta(s) and their receptors in chronic venous leg ulcers. J Invest Dermatol 2001; 117 (5): 1282–9.
16. Costantini S, Capone F, Guerriero E et al. Cytokinome profile of patients with type 2 diabetes and / or chronic hepatitis C infection. PLoS ONE 2012; 7 (6): e39486.
17. Berlanga-Acosta J, Schultz GS, López-Mola E, Guillen-Nieto G, García-Siverio M, Herrera-Martínez L. Glucose toxic eﬀects on granulation tissue productive cells: the diabetics’ impaired healing. Biomed Res Int 2013; 2013: e256043.
18. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular modeling, and wound healing. Int J Vasc Med 2012; 2012: e918267.
19. Sun DP, Yeh CH, So E et al. Interleukin (IL)-19 promoted skin wound healing by increasing fibroblast keratinocyte growth factor expression. Cytokine 2013; 62 (3): 360-8.
20. Beidler SK, Douillet CD, Berndt DF, Keagy BA., Rich PB, Marston WA. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg 2009; 49 (4): 1013–20.
21. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen 2000; 8 (1): 13–25.
22. Jiang L, Dai Y, Cui F et al. Expression of cytokines, growth factors and apoptosis-related signal molecules in chronic pressure ulcer wounds healing. Spinal Cord 2014; 52 (2): 145-51.
23. Bocci V, Zanardi L, Huijberts MSP, Travagli V. Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2011; 5 (1): 45-9.
24. Gracer RI, Bocci V. Can the combination of localized "proliferative therapy" with "minor ozonated autohaemotherapy" restore the natural healing process? Med Hypotheses 2005; 65 (4): 752-9.
25. Re L, Mawsouf MN, Menéndez S, León OS, Sánchez GM, Hernández F. Ozone therapy: clinical and basic evidence of its therapeutic potential. Archives of Medical Research 2008; 39 (1): 17-26.
26. Wainstein J, Feldbrin Z, Boaz M, Harman-Boehm I. Efficacy of ozone-oxygen therapy for the treatment of diabetic foot ulcers. Diabetes Technol Ther 2011; 13 (12): 1255–60.
27. Smith NL, Wilson AL, Gandhi J, Vatsia S, Khan SA. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res 2017; 7 (3): 212-9.
28. Di Mauro R, Cantarella G, Bernardini R et al. The biochemical and pharmacological properties of ozone: the smell of protection in acute and chronic diseases. Int J Mol Sci 2019; 20 (3): 634.
29. Zeng J, Lu J. Mechanisms of action involved in ozone-therapy in skin diseases. Int Immunopharmacol 2018; 56: 235-41.
30. Fuccio C, Luongo C, Capodanno P et al. A single subcutaneous injection of ozone prevents allodynia and decreases the over-expression of pro-inflammatory caspases in the orbito-frontal cortex of neuropathic mice. Eur J Pharmacol 2009; 603 (1-3): 42-9.
31. Sahin H, Simsek T, Turkon H et al. The acute effects of preoperative ozone theraphy on surgical wound healing. Acta Cir Bras 2016; 31 (7): 472-8.
32. Oguz E, Ekinci S, Eroglu M et al. Evaluation and comparison of the effects of hyperbaric oxygen and ozonized oxygen as adjuvant treatments in an experimental osteomyelitis model. J Surg Res 2011; 171 (1): 61-8.
33. Vaillant JD, Fraga A, Díaz MT et al. Ozone oxidative postconditioning ameliorates joint damage and decreases pro-inflammatory cytokine levels and oxidative stress in PG / PS-induced arthritis in rats. Eur J Pharmacol 2013; 714 (1-3): 318-24.
34. Simonetti V, Quagliariello V, Franzini M, Iaffaioli RV, Maurea N, Valdenassi L. Ozone exerts cytoprotective and anti-inflammatory effects in cardiomyocytes and skin fibroblasts after incubation with doxorubicin. Evid Based Complement Alternat Med 2019; 2019: 2169103. doi: 10.1155/2019/2169103.
35. Deng L, Meng W, Li D, Qiu D, Wang S, Liu H. The effect of ozone on hypoxia, hemolysis and morphological change of blood from patients with aortic dissection (AD): a preliminary in vitro experiment of ozonated autohemotherapy for treating AD. Am J Transl Res 2018; 10 (6): 1829-1840.
36. Ameli J, Banki A, Khorvash F, Simonetti V, Jafari NJ, Izadi M. Mechanisms of pathophysiology of blood vessels in patients with multiple sclerosis treated with ozone therapy: a systematic review. Acta Biomed 2019; 90 (3): 213-7.
37. Borrelli E, Diadori A, Zalaffi A, Bocci V. Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study. Int J Ophthalmol 2012; 5 (6): 708-13.
38. Moreno-Fernández A, Macías-García L, Valverde-Moreno R et al. Autohemotherapy with ozone as a possible effective treatment for fibromyalgia. Acta Reumatol Port 2019; 44 (3): 244-9.
39. Nataraj M, Maiya AG, Karkada G et al. Application of topical oxygen therapy in healing dynamics of diabetic foot ulcers - a systematic review. Rev Diabet Stud 2019; 15: 74-82.
40. Wen Q, Chen Q. An overview of ozone therapy for treating foot ulcers in patients with diabetes. Am J Med Sci 2020; 360 (2): 112-9.
41. Juchniewicz H, Lubkowska A. Oxygen-ozone (O2-O3) therapy in peripheral arterial disease (PAD): a review study. Ther Clin Risk Manag 2020; 16: 579-94.
42. Zhang J, Guan M, Xie C, Luo X, Zhang Q, Xue Y. Increased growth factors play a role in wound healing promoted by noninvasive oxygen-ozone therapy in diabetic patients with foot ulcers. Oxid Med Cell Longev 2014; 2014: 273475. doi: 10.1155/2014/273475.
43. Hassanien M, Rashad S, Mohamed N, Elawamy A, Ghaly MS. Non-invasive oxygen-ozone therapy in treating digital ulcers of patients with systemic sclerosis. Acta Reumatol Port 2018; 43 (3): 210-6.
44. Xiao W, Tang H, Wu M et al. Ozone oil promotes wound healing by increasing the migration of fibroblasts via PI3K/Akt/mTOR signaling pathway. Biosci Rep 2017; 37 (6): BSR20170658. doi: 10.1042/BSR20170658.
45. Pchepiorka R, Moreira MS, Lascane NADS et al. Effect of ozone therapy on wound healing in the buccal mucosa of rats. Arch Oral Biol 2020; 119: 104889. doi: 10.1016/j.archoralbio.2020.104889.
46. Taqwim Hidayat A, Thohar Arifin M, Nur M, Muniroh M, Susilaningsih N. Ozonated aloe vera oil effective increased the number of fibroblasts and collagen thickening in the healing response of full-thickness skin defects. Int J Inflam 2021; 2021: 6654343. doi: 10.1155/2021/6654343
47. Leal EC, Carvalho E, Tellechea A et al. Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. Am J Pathol 2015; 185 (6): 1638-48.
48. Dasu MR, Martin SJ. Toll-like receptor expression and signaling in human diabetic wounds. World J Diabetes 2014; 5 (2): 219-23.
49. Dinh T, Tecilazich F, Kafanas A et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes 2012; 61 (11): 2937-47.
50. Acosta JB, del Barco DG, Vera DC et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J 2008; 5 (4): 530-9.
51. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007; 127 (3): 514-25.
52. Dangwal S, Stratmann B, Bang C et al. Impairment of wound healing in patients with type 2 diabetes mellitus influences circulating microRNA patterns via inflammatory cytokines. Arterioscler Thromb Vasc Biol 2015; 35 (6): 1480-8.
53. Houreld NN, Sekhejane PR, Abrahamse H. Irradiation at 830 nm stimulates nitric oxide production and inhibits pro-inflammatory cytokines in diabetic wounded fibroblast cells. Lasers Surg Med 2010; 42 (6): 494-502.
54. Gautam MK, Gangwar M, Singh SK, Goel RK. Effects of Azardirachta indica on vascular endothelial growth factor and cytokines in diabetic deep wound. Planta Med 2015; 81 (9): 713-21.
55. Vinnik IuS, Salmina AB, Tepliakova OV et al. The results of combined ozone therapy using in complex treatment of soft tissues infections in patients with diabetes mellitus type II. Khirurgiia (Mosk) 2015; 2: 63-9.
56. Vairaktaris E, Goutzanis L, Nkenke E et al. Diabetes does not influence oral oncogenesis through fibroblast growth factor receptors. In Vivo 2007; 21 (4): 623-8.
57. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 2006; 14 (5): 558-65.
58. Dekker Nitert M, Barrett HL, Kubala M.H et al. Increased placental expression of fibroblast growth factor 21 in gestational diabetes mellitus. J Clin Endocrinol Metab 2014; 99 (4): 591-8.
59. Piya MK, Harte AL, Chittari MV, Tripathi G, Kumar S, McTernan PG. FGF21 action on human adipose tissue compromised by reduced βKlotho and FGFR1 expression in type 2 diabetes mellitus. Endocrine Abstracts 2013; 31: 179.
60. Kaftan H, Reuther L, Miehe B, Hosemann W, Beule A. Inhibition of fibroblast growth factor receptor 1: influence on tympanic membrane wound healing in rats. Eur Arch Otorhinolaryngol 2012; 269 (1): 87-92.
61. Zhang J, Guan M, Xie C, Luo X, Zhang Q, Xue Y. Increased growth factors play a role in wound healing promoted by noninvasive oxygen-ozone therapy in diabetic patients with foot ulcers. Oxid Med Cell Longev 2014; 2014: 273475. doi: 10.1155/2014/273475.
62. Soares CD, Morais TML, Araújo RMFG et al. Effects of subcutaneous injection of ozone during wound healing in rats. Growth Factors 2019; 37 (1-2): 95-103.
63. Vinnik IuS, Salmina AB, Tepliakova OV et al. Dynamics of local expression of connexin-43 and basic fibroblast growth factor receptors in patients with skin and soft-tissue infections against the background of diabetes mellitus type II. Vestn Khir Im I I Grek 2014; 173 (4): 47-52.
64. Bocci VA. Scientific and ozone therapy. State of the art. Arch Med Res 2006; 37 (4): 425-35.